RVMD - Revolution Medicines, Inc.

101.19
0.700   0.692%

Share volume: 1,561,782
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$100.49
0.70
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
14%
Profitability 0%
Dept financing 15%
Liquidity 43%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.42%
1 Month
5.24%
3 Months
27.06%
6 Months
149.85%
1 Year
155.40%
2 Year
237.98%
Key data
Stock price
$101.19
P/E Ratio 
0.00
DAY RANGE
$100.37 - $102.00
EPS 
-$5.77
52 WEEK RANGE
$29.17 - $124.49
52 WEEK CHANGE
$158.01
MARKET CAP 
15.398 B
YIELD 
N/A
SHARES OUTSTANDING 
198.173 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,082,293
AVERAGE 30 VOLUME 
$2,319,615
Company detail
CEO: Mark A. Goldsmith
Region: US
Website: revmed.com
Employees: 250
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Revolution Medicines, Inc. focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trials for solid tumors, such as gynecologic and colorectal cancer tumors.

Recent news